Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study

OBJECTIVES: To describe the clinical characteristics and predictors of major outcomes in patients treated with tocilizumab (TCZ) for severe COVID-19 pneumonia. PATIENTS AND METHODS: Case series of all sequential patients with severe COVID-19 pneumonia treated with TCZ at an Academic Spanish hospital...

Descripción completa

Detalles Bibliográficos
Autores principales: Moreno-Pérez, Oscar, Andres, Mariano, Leon-Ramirez, Jose-Manuel, Sánchez-Payá, José, Rodríguez, Juan Carlos, Sánchez, Rosario, García-Sevila, Raquel, Boix, Vicente, Gil, Joan, Merino, Esperanza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academic Press 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7365106/
https://www.ncbi.nlm.nih.gov/pubmed/32690352
http://dx.doi.org/10.1016/j.jaut.2020.102523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7365106/
https://www.ncbi.nlm.nih.gov/pubmed/32690352
http://dx.doi.org/10.1016/j.jaut.2020.102523

Ejemplares similares